Universität zu Köln

Klimek, L., Brehler, R., Moesges, R., Demoly, P., Mullol, J., Wang, D. Y., O'Hehir, R. E., Didier, A., Kopp, M., Bos, C. and Karagiannis, E. (2022). Update about Oralair (R) as a treatment for grass pollen allergic rhinitis. Human Vaccines Immunother., 18 (5). PHILADELPHIA: TAYLOR & FRANCIS INC. ISSN 2164-554X

Full text not available from this repository.

Abstract

Sublingual immunotherapy (SLIT) is a well-tolerated, safe, and effective approach to treating allergic rhinitis (AR). Oralair (R) is a five-grass pollen SLIT tablet containing natural pollen allergens from five of the major grass species responsible for seasonal AR due to grass pollen allergy. Recommended use is in a pre-coseasonal regimen, starting daily treatment approximately 4 months before the start of the pollen season, with treatment then continued daily throughout the season; treatment should continue for 3-5 y. Clinical efficacy and safety of Oralair (R) in patients with grass pollen-induced AR has been demonstrated in a comprehensive clinical development program of randomized controlled trials. Effectiveness has been substantiated in subsequent observational studies with sustained efficacy following treatment cessation and a favorable level of adherence, quality of life, benefit, and satisfaction for the patients. Supportive evidence for a benefit in reducing the risk or delaying the development of allergic asthma is emerging.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Klimek, L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Brehler, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Moesges, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Demoly, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mullol, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wang, D. Y. UNSPECIFIED UNSPECIFIED UNSPECIFIED O'Hehir, R. E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Didier, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kopp, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Bos, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Karagiannis, E. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-695035
DOI:	10.1080/21645515.2022.2066424
Journal or Publication Title:	Human Vaccines Immunother.
Volume:	18
Number:	5
Date:	2022
Publisher:	TAYLOR & FRANCIS INC
Place of Publication:	PHILADELPHIA
ISSN:	2164-554X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language SUBLINGUAL IMMUNOTHERAPY TABLETS; COST-EFFECTIVENESS; SUBCUTANEOUS IMMUNOTHERAPY; EFFICACY; SAFETY; MANAGEMENT; RHINOCONJUNCTIVITIS; PATIENT; ASTHMA; TOLERABILITY Multiple languages Biotechnology & Applied Microbiology; Immunology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/69503